It defines our working relationships. We proactively look for ways to create long-term success for everyone: empowering our people to grow, supporting the talent who trust us with their careers, and helping clients to innovate and scale. We’ll always do what we say we will, and we’ll never put someone in a situation we wouldn’t want to be in ourselves.
Diversity, too, is key to our success - from our own boardroom to those of our clients. We’re firmly committed to our DEIB agenda, ensuring people of all backgrounds are represented on our team and improving our process with a broad spectrum of knowledge and experience.
And because our ownership isn’t diluted by external funding, we can make decisions that others can’t. Decisions like ring fencing 30% of RBW’s growing value in an employee trust, so if there’s a positive outcome for the primary shareholders, the whole team shares in what they’ve helped to create.
When we say our work has purpose, we mean it. We’re driven by the knowledge that everything we do contributes to better health outcomes, both indirectly - in placing the talent to achieve our clients’ missions - and directly, enabling more informed decision-making through investment in patient-focussed initiatives.
Patient impact in 2021: Psychological Support at Diagnosis of a Rare Disease
When a patient and their family are faced with a rare disease diagnosis, we understand how confusing, painful and lonely a moment it can be. The mental health impact cannot be underestimated and while there is lots of good news coming from the world of rare diseases – most notably the publication of the 2021 Govt framework – we felt compelled to see if we might be able to support the community in some small way around this specific mental health challenge.
RBW’s Impact work in 2021 aims to see if we can help support the healthcare and rare disease communities in addressing the mental health impact of a diagnosis.
In partnership with Rare Disease Research Partners, we’ve funded research and a literature review that will then be discussed by an advisory panel of leading experts in the field. The panel will publish a white paper outlining their thoughts and recommendations in a peer-reviewed journal later this year. It’s work that we hope will make a tangible difference for patients and those around them, and perhaps be a catalyst for sharing best practice from those on the front line.
And we want our clients to be a part of it. So if you’d like to talk more about the mental health implications of a rare disease diagnosis, meet our research partners or use the findings in your own patient support programme, get in touch.
Patient impact in 2022:
help shape our funding priorities
Our clients serve diverse patient populations. We’re particularly interested to hear about those which are under represented. Would yours benefit from a research study? If so - we want to hear about it.Let’s talk.